BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device
First commercial implantations of the HAART 200 Device for Bicuspid Aortic Valve repair performed by Professor Marek Jasinski at the Wroclaw Medical University
Austin, TX – August 6, 2021 – BioStable Science & Engineering, Inc., announced today that the first commercial implantations of its HAART 200 Aortic Annuloplasty Device were performed on Monday August 2nd by Professor Marek Jasinski, Chief of Cardiac Surgery at Wroclaw Medical University (Wroclaw, Poland). Additional procedures were completed on Thursday August 5th by Professor Marek Deja, Chief of Cardiac Surgery at the Medical University of Silesia (Katowice, Poland). These two respected heart centers were the first selected to receive the HAART 200 Aortic Annuloplasty Device as part of the limited European commercial launch of the technology announced by the company in April.
Professor Jasinski commented “The HAART 200 Aortic Annuloplasty Device is a great addition to our aortic valve repair tool kit providing a new option for the most common congenital heart defect, bicuspid aortic valve disease. Our experience with the HAART 300 Aortic Annuloplasty Devices in trileaflet aortic valve repair has shown us how the devices simplify aortic valve repair and at the same time provide durable annuloplasty. This allows us to expand the benefits of valve repair to more patients. The availability of the HAART 200 Device is critically important because patients with bicuspid aortic valve disease are younger, multiplying the benefits of valve repair vs. replacement.”
Although compelling long-term clinical data suggest that almost all bicuspid aortic valves should be repaired , current repair techniques are complex and not widely adopted. The HAART 200 Device simplifies bicuspid aortic valve repair by stabilizing the annulus and remodeling the valve into a symmetric, 180-degree leaflet orientation, eliminating the need for extensive dissection of the aortic root, and facilitating leaflet repair.
John Wheeler, President and CEO, concluded by saying, “BioStable is very pleased to initiate commercialization of the HAART 200 Aortic Annuloplasty Device alongside the HAART 300 Devices. With the commercial availability of the HAART 200 and HAART 300 Aortic Annuloplasty Devices, BioStable can offer surgeons within the European a comprehensive portfolio of aortic valve repair solutions that addresses all forms of aortic valve insufficiency.”
About BioStable Science & Engineering
BioStable Science & Engineering is a cardiovascular device company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease. The company’s HAART Aortic Repair Technologies are designed to simplify and standardize aortic valve repair, enabling surgeons to offer the recognized clinical benefits of valve repair to patients undergoing surgical correction of aortic insufficiency or aortic aneurysm. To learn more visit www.biostable-s-e.com.
President & CEO
- Miyahara S, Schneider U, Morgenthaler L, Schäfers HJ. (Almost) All Nonstenotic Bicuspid Aortic Valves Should Be Preserved or Repaired. Semin Thorac Cardiovasc Surg. 2019 Winter;31(4):656-660. doi: 10.1053/j.semtcvs.2019.03.008. Epub 2019 Apr 10. PMID: 30980934.